- Home
- RGA vs VTRS Comparison
RGA vs VTRS Comparison
Compare RGA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGA
- VTRS
- Stock Information
- Founded
- RGA 1973
- VTRS 1961
- Country
- RGA United States
- VTRS United States
- Employees
- RGA N/A
- VTRS N/A
- Industry
- RGA Life Insurance
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- RGA Finance
- VTRS Health Care
- Exchange
- RGA Nasdaq
- VTRS Nasdaq
- Market Cap
- RGA 12.1B
- VTRS 11.8B
- IPO Year
- RGA 1993
- VTRS N/A
- Fundamental
- Price
- RGA $188.25
- VTRS $10.61
- Analyst Decision
- RGA Buy
- VTRS Hold
- Analyst Count
- RGA 12
- VTRS 5
- Target Price
- RGA $242.27
- VTRS $10.40
- AVG Volume (30 Days)
- RGA 537.0K
- VTRS 9.5M
- Earning Date
- RGA 07-31-2025
- VTRS 08-07-2025
- Dividend Yield
- RGA 1.98%
- VTRS 4.52%
- EPS Growth
- RGA N/A
- VTRS N/A
- EPS
- RGA 11.51
- VTRS N/A
- Revenue
- RGA $21,751,000,000.00
- VTRS $14,115,700,000.00
- Revenue This Year
- RGA $7.04
- VTRS N/A
- Revenue Next Year
- RGA $10.28
- VTRS $1.85
- P/E Ratio
- RGA $16.35
- VTRS N/A
- Revenue Growth
- RGA 1.76
- VTRS N/A
- 52 Week Low
- RGA $159.25
- VTRS $6.85
- 52 Week High
- RGA $233.81
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- RGA 47.62
- VTRS 72.50
- Support Level
- RGA $185.81
- VTRS $8.74
- Resistance Level
- RGA $189.97
- VTRS $9.03
- Average True Range (ATR)
- RGA 4.92
- VTRS 0.32
- MACD
- RGA 0.62
- VTRS 0.17
- Stochastic Oscillator
- RGA 73.85
- VTRS 90.83
About RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.